Clinical efficacy and tolerability of candesartan cilexetil

Journal of Human Hypertension

Volumn 13, Issue , 1999, Pages S27-S31

  Arakawa, K ^b  

^a OSAKA UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

Author keywords

Candesartan cilexetil; Clinical study; Efficacy; Hypertension; Tolerability

Indexed keywords

2 BUTYL 4 CHLORO 1 (2 NITROBENZYL) 5 IMIDAZOLEACETIC ACID; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; LOSARTAN POTASSIUM; SARALASIN; SARILE; UNCLASSIFIED DRUG;

AGING; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERABILITY; HEADACHE; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MEAN ARTERIAL PRESSURE; META ANALYSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRESSOR RESPONSE; SYSTOLIC BLOOD PRESSURE; TARGET ORGAN; VERTIGO;

ADMINISTRATION, ORAL; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CIRCADIAN RHYTHM; ENALAPRIL; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; JAPAN; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN; RETROSPECTIVE STUDIES; TETRAZOLES; TREATMENT OUTCOME;

EID: 0032963760     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000746     Document Type: Article

References (42)

1. Brunner HR Angiotensin II blockade in man by Sar 1-Ala 8-angiotensin II for understanding and treatment of high blood pressure. Lancet 1973; ii: 1045 - 1048.
2. Ogihara T Angiotensin blockage. Lancet 1974; i: 219.
3. Ogihara T Clinical application of synthetic angiotensin II analogue. Jpn Cire J 1974; 38: 997-1003.
4. Furukawa T Hypotensive imidazole derivatives and hypotensive imidazole-5-acetic acid derivatives. US Patent 4,340,598 and 4,355,042 (1982).
5. Timmermans PBMWM The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists. Am J Hypertens 1991; 4; 275S- 281S.
6. Shibouta T Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-l-[[2'-(lH-tetrazol-5-yl)biphenyl-4-yl] methyl]-lH-benzimidazole-7-carboxylic acid (CV- 11974), and its prodrug, (±)-l-(cyclohexyloxycarbony- loxy)ethyl 2-ethoxy-l-[[2'-(lH-terazol-5-yl)biphenyl-4- yl] methyl] -1 H-benzimidazole-7-carboxylate (TCV- 116).; Pharmacol Exp Ther 1993; 266; 144-150.
7. Noda M Inhibition of rabbit aortic angiotensin II (All) receptor by CV-11974, a new nonpeptide All antagonists. Biochem Pharmacol 1993; 46; 311-318.
8. HC-candesartan cilexetil in healthy volunteers. J Hum Hypertens 1997; 11 (Suppl 2); S27-S28.
9. Nishikawa K Candesartan cilexetil review of its preclinical pharmacology. J Hum Hypertens 1997; 11 (Suppl 2); S9-S17.
10. Morimoto S, Ogihara T. TCV-116: a new angiotensin II type-1 receptor antagonist. Cardiovasc Drug Rev1994; 12: 153-164.
11. Inada Y Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1997; 19: 1079-1099.
12. Wada T et al. Role of angiotensin II in cerebrovascular and renal damages in deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 1995; 13: 113-122.
13. Ogihara T Effects of the angiotensin II receptor antagonist, TCV-116, on blood pressure and the renin- angiotensin system in healthy subjects. Clin Ther1994; 16: 74-86.
14. Ogihara T Pilot study of a new angiotensin II receptor antagonist, TCV-116: effects of a single oral dose on blood pressure in patients with essential hypertension. Clin Ther 1993; 15: 684-691.
15. Ogihara T Open clinical studies on a new angiotensin II receptor antagonist, TCV-116. J Hypertens1994; 12: S35-S38.
16. Nagano M et al. Role of the renin-angiotensin system in hypertension in the elderly. Blood Press Suppl1994; 5: 130-133.
17. Ogihara T Persistent inhibition of the pressor response and aldosterone responses to angiotensin II by TCV-116 in normotensive subjects. J Cardiovasc Pharmacol 1995; 26: 490-494.
18. Delacretaz E Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995; 25: 14-21.
19. Heuer HJ Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (Suppl 2): S55-S56.
20. Fukiyama K Efficacy and safety of TCV-116 (candesartan cilexetil), an angiotensin II receptor antagonist, on essential hypertension in long-term treatment. Rinsho-Iyaku 1996; 12: 3229-3264.
21. Arakawa K Hypotensive effect and safety of TCV- 116 (candesartan cilexetil), a new angiotensin II receptor antagonist, in patients with essential hypertension. Clinical late phase II study. Runsho-Iyaku 1996; 12: 2231-2266.
22. Arakawa M Hypotensive effect and safety of TCV-116 (candesartan cilexetil), a new angiotensin II receptor antagonist, combination therapy with thiazides on essential hypertension. Clinical late phase II study. Rinsho-Iyaku 1996; 12: 2267-2296.
23. Saruta T Efficacy and safety of candesartan cilexetil (TCV-116) on essential hypertension in combination therapy with calcium antagonists. Rinsho-Iyaku1996; 12: 2297-2322.
24. Kajiyama G The effect of TCV-116, an angiotensin II receptor antagonist, on lipid metabolism in patients with essential hypertension. Rinsho-Iyaku1996; 12: 3299-3317.
25. Fujiwara H Effects of TCV-116 (candesartan cilexetil) on left ventricular hypertrophy and glucose tolerance in patients with essential hypertension. Rin- sho-Iyaku 1996; 12: 3281-3297.
26. Iimura O Efficacy and safety of TCV-116 (candesartan cilexetil), a new angiotensin II receptor antagonist, in patients with severe hypertension. Rin- sho-Iyaku 1996; 12: 2323-2364.
27. Fujishima M Efficacy and safety of candesartan cilexetil (TCV-116) in hypertensive patients with renal failure. Rinsho-Iyaku 1996; 12: 2343-2371.
28. Ogihara T Efficacy and safety of TCV-116 (candesartan cilexetil), an angiotensin II receptor antagonist, in the elderly with hypertension. Rinsho- Iyaku 1996; 12: 3211-3228.
29. Arakawa K Evaluation of clinical usefulness of TCV-116 (candesartan cilexetil) in patients with essential hypertension. A double-blind, parallel group-com- parison study using enalapril maleate as control dmg. Rinsyo-Iyaku 1998; 14: 871-918.
30. Arakawa K Effect of candesartan cilexetil, a novel angiotensin II receptor antagonist, on the diurnal blood pressure variation in patients with essential hypertension. Rinsho-Iyaku 1996; 12: 2195-2211.
31. Arakawa K Efficacy and safety of candesartan cilexetil, a novel angiotensin II receptor antagonist, in patients with essential hypertension. Rinsho-Iyaku1996; 12: 2213-2230.
32. Abe K Antihypertensive effect and safety of TCV- 116 (candesartan cilexetil) in patients with essential hypertension. Study with the initial daily dose of 4 mg. Rinsho-Iyaku 1996; 12: 2373-2392.
33. Abe K Antihypertensive effect and safety of TCV- 116 (candesartan cilexetil), an angiotensin II receptor antagonist, in patients with essential hypertension. Study with the initial daily dose of 8 mg. Rinsho-Iyaku1996; 12: 2393-2411.
34. Elmfeldt D Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997; 11 (Suppl 2): S49-S53.
35. Tuck ML Low dose captopril in mild to moderate geriatric hypertension. J Am Ger Soc 1986; 34: 693- 696.
36. Mclnnes GT The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997; 11 (Suppl 2): S75-S80.
37. Zanchetti A Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (Suppl 2); S57-S59.
38. Fanke H. Antihypertensive effects of candesartan cilexetil, enalapril and placebo. J Hum Hypertens1997; 11 (Suppl 2): S61-S62.
39. Andersson OK, Neldam S. A comparison of the antihypertensive effects of candesartan cilexetil and losarían in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (Suppl 2): S63-S64.
40. Farsang C Antihypertensive effects and tolerability of candesartan cilexetil, amlodipine and their combination. Am J Hypertens 1997; 10(4), Part 2: 80A (abstract).
41. Ise T Effects of an angiotensin II receptor antagonist, TCV-116 (candesartan cilexetil) on renal function in essential hypertension. Rinsho-Iyaku 1996; 12: 3265-3280.
42. Mitsunami K Effects of candesartan cilexetil (TCV-116), an angiotensin II receptor antagonist, on cardiac hypertrophy and cardiac function. J New Rem Clin 1996; 45: 1655-1661.